Join our “Ask the Ataxia Expert” session with Dr. Susan Perlman on May 12th at 11:30 AM CDT.  ADD TO CALENDAR

NAF

The Value of Attending AIM

Guest Author: Sokol Todi, PhD; Wayne State University I have been attending the Ataxia Investigators Meeting for nearly a decade. I was a junior faculty at the time of my first participation. I had worked in the Ataxia field for a few years and was looking for a scientific family Read More…

2021 NAF Funded Research

At NAF, we support researchers in many ways, including our grant process. Research grants allow Ataxia investigators to request funding for their studies. Lay summaries are available below for the research grants we funded in 2021.  $655,000 Funded Overall 13 Research Studies Funded Research Seed Money Grants Research Seed Money Read More…

NAF Welcomes Four New Board Members

Above: February 2021 Board of Directors Zoom Meeting NAF recently had a few changes to our Board of Directors. Joe DeCrescenzo, Mike Leader, and Bill Sweeney will be retiring after many years of dedicated service. We thank them for their time, commitment, and passion for the Ataxia community! We are Read More…

Coronavirus Precautions for Ataxia Patients

Last updated: February 2021 The coronavirus (COVID-19) pandemic is affecting communities worldwide. The health and safety of the Ataxia community is a priority at NAF. We have consulted with our Medical and Research Advisory Board, infectious disease specialists, the World Health Organization, and the Centers for Disease Control and Prevention (CDC) Read More…

NAF Joins Efforts with American Brain Coalition

NAF joined efforts spearheaded by the American Brain Coalition (ABC) to create a Neuroscience Center of Excellence at the FDA. We signed on to ABC’s letters to Congress. One letter asks Congresswoman DeGette and Congressman Upton to include the Neuroscience Center of Excellence in their Cures 2.0 legislation. The other letter urges Congressional Neuroscience Caucus co-chairs Read More…

NAF Supports FARA’s Call to Action

Friedreich’s Ataxia Research Alliance (FARA) is encouraging Reata Pharmaceuticals to submit a New Drug Application (NDA) for Omaveloxolone, which recently completed a Phase III clinical trial as a treatment for Friedreich’s Ataxia (FA). FARA is also urging the Food and Drug Administration (FDA) to consider approving the NDA. FARA has Read More…

2019 NAF Funded Research Results

Below are lay summaries submitted for research completed in fiscal year 2019. Each study received a grant from NAF to support their research. To check out more information, click the “+” symbol next to the title of the study. Click the “-” symbol to collapse the lay summary for that Read More…

Ataxia Patient Advocacy Organizations Applaud the US Senate for Passing the Bipartisan “National Ataxia Awareness Day of 2020” Resolution

The National Ataxia Foundation (NAF) and the Friedreich’s Ataxia Research Alliance (FARA) applaud the United States Senate on behalf of Ataxia patients and their families for passing the National Ataxia Awareness Resolution of 2020 (S.Res. 717). Led by U.S Senator Elizabeth Warren (D-MA) and U.S. Senator Cindy Hyde-Smith (R-MS), this Read More…

Want to be a guest blogger?

Submit your name and blog topic. We’ll follow up with submission instructions.

Translate »